Dostarlimab rectal cancer
Treatment with dostarlimab sometimes results in severe infusion-related reactions and immune-mediated effects such as pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies, for example type 1 diabetes or thyroiditis. According to the severity, therapy should be interrupted and a corticosteroid should be given.
Oaknin A, Tinker AV et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6(11):1766-1772
Where is dostarlimab included?
Jemperli contains the active ingredient dostarlimab. How is Jemperli used? Treatment with Jemperli must be initiated and monitored by a doctor experienced in the treatment of cancer. The medicine is available only on a doctor's prescription.
How does dostarlimab work?
How does dostarlimab work? Dostarlimab is supposed to "inhibit certain cancer cells and thus stop the cancer," IQWiG's portal explains. As the study authors explain in the New York Times, the drug is able to unmask cancer cells and help the immune system identify and destroy them.
Is dostarlimab approved in Germany?
[§] Dostarlimab: European Commission grants marketing authorization for first-in-class immunotherapy in recurrent/advanced endometrial cancer. GSK announces that the European Commission has granted conditional marketing authorization for dostarlimab (Jemperli).
Dostarlimab health insurance
Immune-mediated endocrinopathies, including hypothyroidism, hyperthyroidism, thyroiditis, hypophysitis, type 1 diabetes mellitus, diabetic ketoacidosis, and adrenal insufficiency have been reported in patients receiving dostarlimab (see section 4.8).
past 2 years; immunodeficiency or receipt of immunosuppressive therapy within 7 days; active HIV, hepatitis B, or hepatitis C infection; active autoimmune disease requiring systemic therapy, excluding replacement therapy, within the past 2 years; history of interstitial lung disease; administration of a live vaccine within 14 days.
The safety profile did not differ in patients with dMMR/MSI-H endometrial carci- nom in the GARNET study (n = 153) from that in the overall monotherapy population (see Table 3).
A PK population analysis of patient data suggests that there are no cli- nically relevant effects of age (range: 24 to 86 years), gender or race, ethnicity, or tumor type on clearance of dostarlimab.
1 Fachinformation Jemperli, Stand: April 2021 2 Endometriumkrebs-Statistik. World Cancer Research Fund. https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. Veröffentlicht 2018. (zuletzt aufgerufen: Januar 2021)3 Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;1-15.4 Zamarin D, Jazaeri AA: Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 2016; 141: 86-945 Oaknin A, Tinker AV, Gilbert L et al: Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: Eine nicht-randomisierte klinische Phase-1-Studie. JAMA Oncol. 20206 Laken H, Kehry M, Mcneeley P, et al. Identifizierung und Charakterisierung von TSR-042, einem neuartigen therapeutischen Antikörper gegen menschliches PD-1. European Journal of Cancer. 2016;69,S102. doi:10.1016/s0959-8049(16)32902-1.
Larotrectinib is a so-called NTRK blocker, which is currently being tested in a clinical trial, including at KiTZ, in young cancer patients with an NTRK gene fusion. The NTRK gene, which is actually harmless, can become an oncogene when it fuses with another gene. This means when two parts of actually different genes come together to form a completely new gene.
Because Lana's tumor tested positive for such a gene fusion, she is eligible to participate in this global study. The hope is that larotrectinib can prevent the uncontrolled growth of her tumor.